BioArctic AB (publ) (BIOABS.XC)

279.80 0.00 (0.00%) At close: 04:10PM BST

BioArctic AB (publ)

Warfvinges vag 35
Stockholm 112 51
Sweden
46 86 95 69 30
https://www.bioarctic.se

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 90

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Gunilla Osswald Ph.D.	President & CEO	8.75M	N/A	1961
Dr. Pär Gellerfors	Co-Founder, Senior VP of Business Strategy & Director	390k	N/A	1947
Prof. Lars Lannfelt	Co-Founder, Senior VP of Medical science & Director	2.54M	N/A	1949
Mr. Anders Martin-Lof M.B.A., M.Sc.	Chief Financial Officer	N/A	N/A	1971
Ms. Johanna Fälting	Chief Research Officer & Head of Research	N/A	N/A	1972
Mr. Christer Möller	VP of Pre-Clinical Development & Chief Scientific Officer	N/A	N/A	1959
Mr. Oskar Bosson	VP and Head of IR & Communication	N/A	N/A	1976
Mr. Leif Gallo LL.M.	General Counsel and Head of Legal & IP	N/A	N/A	1959
Mr. Harald Borgeke	Head of Public Affairs	N/A	N/A	N/A
Ms. Frida Lekander	Head of Marketing	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814, ND3014, andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.

Corporate governance

BioArctic AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.